Lipocine
LPCN
18 hedge funds and large institutions have $2.44M invested in Lipocine in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0.24% more ownership
Funds ownership: 9.94% → 10.18% (+0.24%)
5% less funds holding
Funds holding: 19 → 18 (-1)
44% less capital invested
Capital invested by funds: $4.38M → $2.44M (-$1.94M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$73.5K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$30.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.21K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$2.04K |
Top Sellers
| 1 |
Two Sigma Advisers
New York
|
-$106K |
LPCN Hedge Fund Activity: Q3 2024 in Review
18 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2024, worth a combined $2.44M — down 44% from $4.38M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LPCN and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $73.5K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $106K sold.
- 18 institutional investors held Lipocine (LPCN) as of Q3 2024, down from 19 in Q2 2024.
- Funds reported $2.44M of Lipocine stock for Q3 2024, down 44% quarter-over-quarter.
- 1 fund opened new Lipocine positions in Q3 2024 and 2 closed out, a net change of -1 holder.
- The largest Lipocine buyer in Q3 2024 was Renaissance Technologies, an estimated $73.5K added.
- The largest Lipocine seller in Q3 2024 was Two Sigma Advisers, an estimated $106K sold.
Based on aggregated 13F filings for Q3 2024.